Conference Committees

IPVS 2025 Conference Co-Chairs

Anna R. Giuliano

USA

Anna R. Giuliano, PhD, is the founding director of the Center for Immunization and Infection Research in Cancer (CIIRC) at the Moffitt Cancer Center in Tampa, Florida. Dr Giuliano’s career had its inception in the relationship between human papillomavirus (HPV) infections and cervical cancer, and has evolved over the past 35 years to encompass penile, anal, and oral cancers in men, as well as other infectious diseases and their causal relationships with various cancers. Her work has contributed significantly to our understanding of HPV natural history and to HPV vaccine protection against multiple diseases in women and men.
An expert in the field of cancer research she has led numerous studies conducted globally. Dr Giuliano was a contributor to the 1999 Institute of Medicine (IOM) report titled The Unequal Burden of Cancer and the 2005 International Agency for Research on Cancer (IARC) report that concluded for the first time that HPV is a cause of multiple cancers in women and men. In 2013, at the American Cancer Society (ACS) 100th anniversary, she was the recipient of the ACS Distinguished Achievement in Cancer Award. In 2018, she was selected for the ACS Clinical Research Professor Award for “Prevention of Infection-Related Cancers.” In 2019, Dr. Giuliano received the American Society of Preventive Oncology (ASPO) Fraumeni Distinguished Lifetime Achievement Award.
Dr Giuliano has authored >500 peer-reviewed publications.

Siriwan Tangjitgamol

Thailand

Education
1983: BS Pharmacy, Southwestern university, Philippines
1987: Doctor of Medicine, Gullas college of Medicine, Philippines
1992: Board of Anatomical Pathology, Siriraj hospital, Thailand
1998: Board of Obstetrics and Gynecology, BMA Medical college and Vajira hospital, Thailand
2000: Board of Gynecologic Oncology, BMA Medical college and Vajira hospital, Thailand
2002: Board of Family Medicine, Thai Medical Council, Thailand
2004: Postdoctoral fellow in Gynecologic Medical Oncology, MDAnderson Cancer Center, University of Texas, Houston, Texas
2012: Board of Gynecologic Pathology, The Royal Thai College of Anatomical Pathology, Medical Council, Thailand
Professional Appointment:
1989-1995: Staff member of Anatomical Pathology division, National Cancer Institute of Thailand
1995-2020: Staff member of Obstetrics and Gynecology Department, Faculty of Medicine Vajira Hospital
2008-2011: Chair of Anatomical Pathology Department, Faculty of Medicine Vajira Hospital
2014-2018: Deputy Dean of Research and Academic Affair, Faculty of Medicine Vajira Hospital
2020-2021: Vice President, Thai Gynecologic Cancer Society
2020-2022: Chair of Scientific Committee, Royal Thai College of Obstetrics and Gynaecology
2022-2023: President-elect, Thai Gynecologic Cancer Society
2024-2025: President, Thai Gynecologic Cancer Society
Professional Experience
 Principal Editor of Journal Gynecologic Oncology since 2020 until present

IPVS 2025 Program Organizing Committee

Aimeé Kreimer

POC Chair

Dr. Kreimer is a Senior Investigator at the US National Cancer Institute, Division of Cancer Epidemiology and Genetics. She focuses her research on the etiology and prevention of human papillomavirus (HPV) and cancers at multiple sites, including the head and neck and anogenital region. She has particular interests in translational research, cancer etiology related to the natural history of HPV infection at multiple anatomic sites, and cancer prevention. She leads investigations on associations between HPV serostatus and risk of HPV-driven oropharyngeal cancers. She is the Principal Investigator on several prophylactic HPV vaccine trials including “ESCUDDO: A Randomized Trial of One-Dose HPV Vaccination,” a research initiative of the Cancer Moonshot.

Anna-Barbara Moscicki

Clinical Science Chair

Dr. Moscicki is Professor of Pediatrics at UCLA, Chief, Division of Adolescent and Young Adult Medicine, Associate Executive Chair for Clinical Research, and Chair, Clinical Trials Committee for Pediatrics. Dr. Moscicki’s 35+ year career has focused on adolescent gynecology and sexually transmitted infection research with a specific focus in Human Papillomavirus, HIV infection and mucosal immunology. Dr. Moscicki was the principle investigator of a natural history study of HPV in adolescents and young women that followed women for 25 years, one of the longest running HPV cohorts. Her work on the natural history included defining persistence and clearance, mucosal and systemic immune responses to HPV and the role of the microbiome and HPV clearance. She has served on numerous national and international committees, including the W.H.O., N.I.H., American Society for Colposcopy and Cervical Pathology (ASCCP), and the American Cancer Society. She is a Past President of ASCCP. Her work was highly influential in forming the new cervical cancer screening guidelines and triage of abnormal cytology in young women in the US. She is also involved in health outcomes in perinatally HIV infected children including sexual risk behaviors, substance use, oral health, microbiomes, and HPV and has worked with numerous Networks on HIV disease in children and adolescents. She was a working group chair for the new ASCCP Risk-Based Management Guidelines.

Ann Burchell

Public Health Chair

Dr. Ann Burchell, Canada Research Chair in Sexually Transmitted Infection Prevention, uses epidemiological data to improve prevention and health care for HPV, HIV, and other STIs and minimize the complications associated with these diseases. She and her research team hope to promote sexual health for all by supporting effective and practical strategies to prevent STIs and related cancers in high-risk populations. Dr. Burchell is a scientist with MAP Centre for Urban Health Solutions in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, and Research Director of St. Michael’s Department of Family and Community Medicine. She is also a scientist with ICES, an Associate Professor in the University of Toronto’s Faculty of Medicine (Department of Family and Community Medicine) and Dalla Lana School of Public Health (Division of Epidemiology).

Karl Munger

Basic Science Chair

Karl Munger earned his bachelor's and Ph.D. degrees in Biochemistry from the University of Zurich, Switzerland. After a postdoctoral fellowship at the National Cancer Institute/National Institutes of Health in Bethesda, MD, he became a faculty member at Harvard Medical School, where he moved through the ranks and was promoted to Professor of Medicine in 2013. He moved to Tufts in 2014, where he currently serves as the Dorothy Todd Bishop Research Professor and Chair of the Department of Developmental, Molecular, and Chemical Biology at Tufts University School of Medicine.

Suzanne Garland

Interdisciplinary Chair

Department of Microbiology and Infectious Diseases, Royal Women’s Hospital, Department of Microbiology, RCH Honorary Research Fellow, Murdoch Childrens Research Institute Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne, Australia

Staci Sudenga

Early Career Researchers

Dr. Staci Sudenga is an Assistant Professor of Medicine in the Division of Epidemiology at Vanderbilt University Medical Center. She is the Chair of the Early Career Research Committee for the International Papillomavirus Society. Dr. Sudenga’s research focuses on infections and cancer, the natural history of infections, and the synergy between infections. Her goal as a molecular epidemiologist is to conduct research in clinical cohort studies in order to identify biomarkers that increase the risk for cancer that can be translated into primary prevention efforts, early diagnosis, or treatment.

Andreia-Albuquerque_Photo-1-e1637587967206

Andreia Alburqueque

Special Interest Satellite Symposia

Dr. Andreia Albuquerque, MD, PhD, is a Consultant Gastroenterologist and Associate Professor with a keen focus on early detection and the prevention of anal cancer. She has authored over 80 peer-reviewed publications, including first-author contributions in The Lancet Gastroenterology and Hepatology, Journal of Crohn’s and Colitis, Clinical Infectious Diseases, British Journal of Cancer, and the International Journal of Cancer.

Dr. Albuquerque currently serves as a Board Member of the International Papillomavirus Society (IPVS), chairs the IPVS Social Media Committee, and is a member of the IPVS Education Committee. She also co-directed the inaugural edition of the IPVS Human Papillomavirus-Related Anogenital Diseases Course for Clinicians (IPVS PACC) and the IPVC 2024 High-Resolution Anoscopy Workshop.

Joel Palefsky

Awareness Program

Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine and Infectious Diseases at the University of California San Francisco School of Medicine. He trained in medicine and Internal Medicine at McGill University in Montreal Canada and in Infectious Diseases at Stanford University. He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the founder and director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center. He is the vice-chair of the National Cancer Institute (NCI)-supported AIDS Malignancy Consortium. He is the chair of the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study, a national multi-site NIH study that showed that treatment of anal cancer precursor lesions prevents the development of anal cancer. He is founder and past president of the International Anal Neoplasia Society and is past president of the International Papillomavirus Society. He is founder and chairman of the International Papillomavirus Society International HPV Awareness campaign.

Laura Sichero

Scholars Program

Research Coordinator at the Cancer Institute of the State of São Paulo and a Collaborator Professor at the Faculty of Medicine, University of São Paulo (USP), São Paulo, Brazil. I have a broad background in Molecular Virology, with specific training and expertise in molecular biology, molecular epidemiology, and biochemistry. Research focuses on the understanding of the impact of mucosal and cutaneous HPV genetic variability upon associated disease development and biological and biochemical properties of infected cells. Further involved in studying HPV transcription and the use of transcription factors as prognostic biomarkers and therapeutic targets.

Basic Science Committee

Karl Munger

Basic Science Chair

Frank Stubenrauch

Germany

Dr. Stubenrauch is a senior group leader at the Institute for Medical Virology and Epidemiology of Viral Diseases at the Eberhard-Karls-University Tuebingen in Germany. His research focuses on the understanding of the viral life cycle using tissue culture and animal model systems.

Cary Moody

USA

Elizabeth White

USA

Laura Sichero

Brazil

Arkom Chaiwongkot

Thailand

Clinical Science Committee

Anna-Barbara Moscicki

Clinical Science Chair

Richard Hillman

Australia

Professor Richard Hillman runs the Dysplasia & Anal Cancer Services within the Department of HIV & Immunology, St Vincent’s Hospital, Sydney. He developed High Resolution Anoscopy in Sydney during the initial efficacy trials for Gardasil in 2004. Since then, he has been President of the International Anal Neoplasia Society, where he was involved in the development of international guidelines for High Resolution Anoscopy, and anal cancer screening. He has published over 140 peer-reviewed articles, including in the Lancet and New England Journal of Medicine.

Kimon Chatzistamatiou

Greece

Dr Kimon Chatzistamatiou is an academic consultant in the 1st Department of Obstetrics and Gynecology at the Aristotle University of Thessaloniki, Greece. He received his MD (2002) and PhD (2017) from the Medical School of the Aristotle University of Thessaloniki. He is board-certified in Obstetrics and Gynecology (2013), certified in colposcopy and cervical pathology (2014), and has overseen the lower genital tract clinic at “Papageorgiou” General Hospital in Thessaloniki, Greece, since 2018.

Siriwan Tangjitgamol

Thailand

Patravoot Vatanasapt

Thailand

Public Health, Epidemiology & Implementation Science Committee

Ann Burchell

Public HealthChair

Tim Waterboer

Germany

Annette Sohn

Thailand

Dr. Annette Sohn is the Director of TREAT Asia and a Vice President of amfAR – The Foundation for AIDS Research in Bangkok, Thailand. She directs a program integrating HIV, co-infection, and co-morbidity research among children, adolescents, and adults through a network of program partners across 13 Asia-Pacific countries, with related activities around research training and community advocacy. She chairs the Executive Committee of the US NIH’s IeDEA global cohort consortium (International Epidemiology Databases to Evaluate AIDS) and is a co-Editor-in-Chief of the Journal of the International AIDS Society. Dr. Sohn obtained her medical degree from the University of California, Los Angeles, and her PhD in global health from the University of Amsterdam. She did her pediatrics and pediatric infectious diseases training at the University of California, San Francisco, where she is a volunteer associate clinical professor in the Department of Pediatrics.

Nittaya Phanuphak

Thailand

Yin Ling Woo

Malaysia

Interdisciplinary Sub-Committee

Suzanne Garland

Interdisciplinary Chair

Prof. Reproductive & Neonatal Infectious Diseases, Department of Obstetrics and Gynaecology, University of Melbourne, Director Centre Women’s Infectious Diseases Research, Royal Women’s Hospital and Honorary Research Fellow, Infection & Immunity, Murdoch Children’s Research Institute.

Richard Roden

USA

Richard Roden, PhD, is a Professor in the Departments of Pathology, Gynecology and Obstetrics, and Oncology at the Johns Hopkins University School of Medicine. He has co-led the Johns Hopkins Kimmel Cancer Center's Cancer Prevention and Control Program for 10 years. His research focuses on approaches to prevent and treat cervical cancer through the development of novel vaccines and small molecule proteasome inhibitors. Dr. Roden’s team is currently engaged in the early clinical development of a minor capsid antigen L2-based vaccine that is active against all oncogenic types of human papillomavirus (HPV). He is also working on immunotherapy phase I trials to test their potential to treat HPV infections and dysplasia, thereby interrupting progression to cervical cancer.

Chemtai Mungo

USA

Dr. Mungo is an Assistant Professor of Obstetrics and Gynecology and a Physician-Scientist at the University of North Carolina, Chapel Hill (UNC-CH). She earned her MD from the University of California, San Francisco, and a Master of Public Health from the Johns Hopkins School of Public Health. Her research is focused on secondary prevention of cervical cancer in low- and middle-income countries. Specifically, she is investigating the feasibility of self-administered intravaginal therapies for HPV and cervical precancer in these settings.

Dr. Mungo has authored over 30 peer-reviewed publications and was named an ASCO Young Investigator in 2021. In 2022, she received the American Association of Cancer Research (AACR) Global Fund for Women's Cancers Career Development Award and was recognized as an AACR Next Generation Star. In 2023, she was named an NCI Division of Cancer Prevention Early Career Scientist. Dr. Mungo leads Phase I/II clinical trials of repurposing generic therapies with antiviral or cytotoxic properties for cervical precancer treatment in Kenya.

Early Career Program Sub-Committee (ECR)

Staci Sudenga

ECR Chair

Dr. Staci Sudenga is an Assistant Professor of Medicine in the Division of Epidemiology at Vanderbilt University Medical Center. Dr. Sudenga’s research focuses on infections and cancer, the natural history of infections, and the synergy between infections. Her goal as a molecular epidemiologist is to conduct research in clinical cohort studies in order to identify biomarkers that increase the risk for cancer that can be translated into primary prevention efforts, early diagnosis, or treatment. Dr. Sudenga has several funded projects focused on early detection and biomarkers related to anal cancer.

Ethan Morgan

Renee King

USA

Mariano Molina

Netherlands

Federica Inturrisi

USA

Natacha Phoolcharoen

Thailand

Awareness Program Sub- Committee

Joel Palefsky

Chair

M.D., C.M., F.R.C.P.(C). Professor of Medicine at the University of California San Francisco School of Medicine. His interests include the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center. He is the chair of the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study, a national multi-site NIH study designed to determine whether treatment of anal cancer precursor lesions prevents the development of anal cancer. He is the founder and past president of the International Anal Neoplasia Society and is the past president of the International Papillomavirus Society (IPVS). He continues to serve on the board of IPVS and leads the IPVS International HPV Awareness Day Campaign.